Janssen Submits Paliperidone Palmitate 6-Month (PP6M) Supplemental New Drug Application to U.S. FDA for Treatment of Schizophrenia in Adults ...Middle East

TITUSVILLE, N.J., Nov. 2, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for paliperidone palmitate 6-month (PP6M) for the...

Read More Details
Finally We wish PressBee provided you with enough information of ( Janssen Submits Paliperidone Palmitate 6-Month (PP6M) Supplemental New Drug Application to U.S. FDA for Treatment of Schizophrenia in Adults )

Also on site :

• Morning Report — Texas braces for more flood danger after Hill Country tragedy 
• Bangladesh lawyers challenge ex-PM Hasina’s murder trial charges
• Ukraine plagued by ‘palace politics’ and purges – Economist